atorvastatin + misoprostol

This investigational drug regimen, developed by the University of Utah, combines high-dose atorvastatin with misoprostol for the termination of early pregnancy (35-49 days gestational age). Atorvastatin is a well-known HMG-CoA reductase inhibitor typically used for cholesterol management, but in this experimental context, it is administered at 80 mg daily for seven days to evaluate its potential to interfere with pregnancy progression. This is followed by a dose of misoprostol (800 mcg), a prostaglandin E1 analog that induces uterine contractions. The regimen is being studied as a potential alternative or adjunct to the standard mifepristone-misoprostol protocol in a pilot clinical trial (NCT05342974) conducted at the Planned Parenthood Association of Utah.

Other names

atorvastatin and misoprostol regimenatorvastatin for medication abortion